BJUI compass最新文献

{"title":"Association between insulin resistance and prostate volume: A 4-year analysis from the Reduction by Dutasteride of Prostate Cancer (REDUCE) Trial","authors":"James P. Daniels,&nbsp;Alexander Hernández-Tirado,&nbsp;James Mirocha,&nbsp;Renning Zheng,&nbsp;Jordan Palmer,&nbsp;Daniel Moreira,&nbsp;Stephen J. Freedland","doi":"10.1002/bco2.70085","DOIUrl":"10.1002/bco2.70085","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Most, but not all studies, suggest insulin resistance is associated with benign prostatic hyperplasia, but its impact on prostate volume (PV) changes over time remains unclear. We examined whether higher insulin resistance, measured by Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), is associated with larger PV and greater prostate growth over a 4-year period.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>We analysed data from the 4-year, randomized, double-blind, placebo-controlled REDUCE trial testing whether dutasteride could prevent prostate cancer. Patients underwent transrectal ultrasound measuring PV at baseline, year 2 and year 4. We calculated HOMA-IR from baseline fasting glucose and insulin, then stratified patients into quartiles within each arm (placebo vs. dutasteride). Using multivariable models, we estimated PV changes over time. We conducted a sensitivity analysis excluding patients with diabetes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Higher HOMA-IR quartiles were associated with larger PV at baseline, year 2 and year 4 in both placebo and dutasteride arms (all p &lt; 0.001), though absolute differences were modest. PV increased in the placebo arm over 4 years, whereas it decreased in the dutasteride arm. However, there was no significant association between HOMA-IR and PV change in either arm. Results remained unchanged after excluding patients with diabetes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Patients with higher HOMA-IR had modestly larger PVs at baseline, year 2 and year 4, but insulin resistance was unrelated to PV change over four years. These findings suggest that insulin resistance may be a modifiable risk factor contributing to benign prostatic enlargement, though further research is needed to determine its clinical relevance.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72420,"journal":{"name":"BJUI compass","volume":"6 9","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://bjui-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/bco2.70085","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145057930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ureteral stent symptoms: A systematic review and meta-analysis comparing the use of mirabegron and tamsulosin","authors":"Daniel Madarshahian,&nbsp;Abdulrasheed Habeeb,&nbsp;Nimeshan Chandra-Segaran,&nbsp;Kesavapilla Subramonian,&nbsp;Keval Patel","doi":"10.1002/bco2.485","DOIUrl":"10.1002/bco2.485","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Ureteral stent insertion, crucial for managing ureteral obstructions, often results in stent-related symptoms (SRSs) adversely affecting patient quality of life. This meta-analysis compares the effectiveness of tamsulosin or mirabegron versus placebo in alleviating these symptoms.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Following PRISMA guidelines, we systematically reviewed randomized controlled trials (RCTs) comparing mirabegron or tamsulosin to placebo in managing SRSs. Data sources included PubMed, Embase, Web of Science and CENTRAL, up to November 2023. The inclusion criteria focused on studies reporting on Ureteral Stent Symptom Questionnaire (USSQ), International Prostate Symptom Score (IPSS), quality of life (QoL) assessments, analgesic usage and adverse events. Meta-analysis employed a random-effects model, assessing heterogeneity and publication bias. For assessing the risk of bias in the included randomized trials, we employed the Cochrane Collaboration's tool. This protocol was registered at the International Prospective Register of Systematic Reviews (registration number: CRD42024511842).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Sixteen RCTs with 1635 patients met the inclusion criteria. Tamsulosin significantly improved body pain (MD −1.80; 95% CI −3.53 to −0.07; <i>p</i> = 0.04), sexual function (MD −0.63; 95% CI −1.16 to −0.10; <i>p</i> = 0.02) and improved quality of life score (MD −2.36; 95% CI −3.56 to −1.17; <i>p</i> = 0.0001), while mirabegron was more effective in reducing urinary symptoms (MD −8.71; 95% CI −15.81 to −1.61; <i>p</i> = 0.02), enhancing general health (MD −2.58; 95% CI −3.78 to −1.37; <i>p</i> &lt; 0.0001) and reducing analgesia use (MD −1.56; 95% CI −2.70 to −0.41; <i>p</i> = 0.008). Both medications significantly reduced total International Prostate Symptom Score (Tamsulosin MD −8.4; 95% CI −15.63 to −1.22; <i>p</i> = 0.02; Mirabegron MD −6.29; 95% CI −8.50 to −4.08; <i>p</i> &lt; 0.00001) without a significant rise in adverse events (tamsulosin OR 1.90; 95% CI 0.40–9.18; mirabegron <i>p</i> = 0.42 and OR 0.93; 95% CI 0.30–2.88; <i>p</i> = 0.89).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Tamsulosin and mirabegron effectively manage SRSs, with distinct benefits in different symptom domains. This suggests a potential for complementary therapeutic strategies. Future high-quality RCTs are needed to explore their combined efficacy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72420,"journal":{"name":"BJUI compass","volume":"6 9","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://bjui-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/bco2.485","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145038253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential gains from radical treatment of men with prostate cancer according to life expectancy","authors":"Sandra Irenaeus,&nbsp;Hans Garmo,&nbsp;Rolf Gedeborg,&nbsp;Mats Ahlberg,&nbsp;David Robinson,&nbsp;Pär Stattin,&nbsp;Kerri Beckmann","doi":"10.1002/bco2.70076","DOIUrl":"10.1002/bco2.70076","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To investigate the impact of age and life expectancy on treatment decisions and its consequences for outcomes among men with intermediate and high-risk prostate cancer (PCa).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and methods</h3>\u0000 \u0000 <p>We studied men in Prostate Cancer data Base Sweden (PCBaSe) diagnosed between 2008 and 2022 with intermediate-risk or high-risk localized or locally advanced PCa and life expectancy between 2.5 and 15 years in the absence of PCa. Estimates of life expectancy were based on age and two comorbidity indices.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 32 196 men were included in the analyses. Of these, 17 419 (54%) had a life expectancy between 10 and 15 years, of whom 11 147 (64%) received primary radical treatment. Age had a stronger influence than life expectancy on the selection of treatment. Around 10% of deaths within 10 years of diagnosis could potentially have been avoided if men with &gt;10 years life expectancy, regardless of age, had received radical treatment, based on assumptions of high treatment efficacy (30% reduction in all-cause mortality) and high uptake of treatment (90%).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>A substantial proportion of healthy older men with intermediate and high-risk PCa did not undergo radical treatment. According to our model and assumptions, 10% of deaths within 10 years of diagnosis in these men could potentially have been avoided if they had received radical treatment.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72420,"journal":{"name":"BJUI compass","volume":"6 9","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://bjui-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/bco2.70076","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145037720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Life after radical cystectomy: A mixed-methods targeted review of patient-reported quality of life following bladder removal","authors":"Ingolf Griebsch,&nbsp;Kristian Juul,&nbsp;Andrew Bottomley,&nbsp;Roya Sherafat-Kazemzadeh,&nbsp;Jack Pemment,&nbsp;Tori Brooks,&nbsp;Rocco Adiutori,&nbsp;Sonia Bothorel","doi":"10.1002/bco2.70049","DOIUrl":"10.1002/bco2.70049","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Radical cystectomy (RC) is a life-altering surgery primarily used to treat muscle-invasive bladder cancer (MIBC) and, occasionally, high-risk non-muscle-invasive bladder cancer (NMIBC). While this procedure can be lifesaving, it often leads to significant changes in quality of life (QOL). This review synthesizes the current quantitative and qualitative literature on QOL outcomes for RC patients, highlighting areas of impact and minimal recovery post RC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A targeted literature review was conducted in Medline, searching for studies using qualitative methods to report patient experience and important aspects of QOL outcomes among RC patients between 2013 and 2024. A second search was performed focusing on clinical studies that reported QOLs using quantitative methods. Studies were screened based on study population and type of reported outcomes. Nine qualitative studies were selected to identify important themes related to QOL concepts. There were seven quantitative studies that were selected to extract the results of reported patient outcomes. These results were categorized using the themes identified (Sexual Functioning, Physical Functioning, Emotional Functioning, Work Functioning, Activities of Daily Living and Family-Social Functioning). Key QOL areas were examined and organized by the severity of impairment and potential for recovery.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Patients experienced disease impact on sexual functioning and physical mobility as well as emotional well-being, daily living activities, work functioning and social interactions, with the first two domains most profoundly affected by RC. Emotional challenges and dependence on family support were prevalent post RC, with some gradual improvements in the second year. Qualitative findings also underscore the complex emotional and social adjustments patients undergo.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This review highlights the extensive impact of RC on multiple dimensions of QOL, suggesting a critical need for improved patient counselling and long-term support strategies. The findings highlight the importance of educating patients about the potential changes in QOL when considering treatment options. With shared patient and clinician decision making in specific cases of NMIBC, bladder sparing strategies may be considered, depending on the clinical contexts and patients' individual needs.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72420,"journal":{"name":"BJUI compass","volume":"6 9","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://bjui-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/bco2.70049","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145037748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute kidney injury as a predictor of infectious complications after mini-PCNL","authors":"Angelo Cormio,&nbsp;Daniele Castellani,&nbsp;Domenico De Palma,&nbsp;Ruggiero Fiorella,&nbsp;Runeel Ratnayake,&nbsp;Michele Lotito,&nbsp;Giuseppe Albino,&nbsp;Ugo Giovanni Falagario,&nbsp;Gian Maria Busetto,&nbsp;Carlo Bettocchi,&nbsp;Giuseppe Carrieri,&nbsp;Luigi Cormio","doi":"10.1002/bco2.70084","DOIUrl":"10.1002/bco2.70084","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To investigate the incidence, risk factors and clinical consequences of acute kidney injury (AKI) following mini-percutaneous nephrolithotomy (mini-PCNL), with particular focus on its association with postoperative infectious complications.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>A retrospective analysis was conducted on 496 adult patients who underwent mini-PCNL (22 Ch) between February 2020 and April 2025. AKI was defined according to KDIGO criteria as either a ≥ 1.5-fold increase or an absolute increase of ≥0.3 mg/dl in serum creatinine within 72 hours postoperatively. Patients were stratified into AKI and non-AKI groups. Multivariable logistic regression analyses were performed to identify predictors of AKI development and infectious complications.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Surgery was done in spinal anaesthesia in all cases. AKI occurred in 45 patients (9.1%). There was no difference in median surgical time (52.5 vs 55.0 minutes, p = 0.33) between groups. There was no difference between the two groups in gender distribution, median age, body mass index, baseline serum creatinine, rates of comorbidities and stone features. Patients with AKI had significantly higher rates of overall postoperative complications (24.4% vs 7.1%, p &lt; 0.001) and longer hospital stays (4 vs 3 days, p &lt; 0.001). Infectious complications were significantly more frequent in the AKI group, with higher median procalcitonin levels (0.21 vs 0.06 ng/ml, p = 0.03). One patient in the AKI group died from sepsis. Multivariable analysis identified previous PCNL (OR 2.51, 95% CI 1.33–4.72, p &lt; 0.01) and higher baseline serum creatinine (OR 2.00, 95% CI 1.07–3.73, p = 0.03) as independent predictors of AKI. AKI was the only independent predictor of infectious complications (OR 3.47, 95% CI 1.04–11.58, p = 0.04).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The strong association between AKI and infectious complications, including potential mortality from sepsis, highlights the clinical significance of this underreported complication. Enhanced perioperative monitoring and aggressive management of infectious complications are warranted in patients who develop AKI following mini-PCNL.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72420,"journal":{"name":"BJUI compass","volume":"6 9","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://bjui-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/bco2.70084","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145012303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “Therapy de-escalation for testicular cancer (THERATEST): A multi-centre observational cohort feasibility study of de-escalation therapies for good prognosis stage II germ cell tumours”","authors":"","doi":"10.1002/bco2.70071","DOIUrl":"10.1002/bco2.70071","url":null,"abstract":"<p>Aziz NA, Ng K, Alifrangis C, Tran B, Conduit C, Liow E, et al. <b>Therapy de-escalation for testicular cancer (THERATEST): A multi-centre observational cohort feasibility study of de-escalation therapies for good prognosis stage II germ cell tumours</b>. BJUI Compass. 2025; 6(8):e70057. https://doi.org/10.1002/bco2.70057.</p><p>In the originally published article, Section 3.2—<i>Secondary Objectives and Endpoints—</i>was not presented in the correct sequence. While the content is factually accurate, the structure is disordered and several objectives are repeated or misaligned, which may confuse readers. The correct version appears below.</p><p><b>3.2 | Secondary objectives and endpoints</b></p><p>We apologize for this error.</p>","PeriodicalId":72420,"journal":{"name":"BJUI compass","volume":"6 9","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://bjui-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/bco2.70071","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145012304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a novel risk model to predict CRPC progression following IMRT: Implications for tailoring treatment intensity","authors":"Takashi Ogata,&nbsp;Rihito Aizawa,&nbsp;Hiroyasu Abe,&nbsp;Takayuki Goto,&nbsp;Kiyonao Nakamura,&nbsp;Yuki Kita,&nbsp;Takayuki Sumiyoshi,&nbsp;Kaoru Murakami,&nbsp;Kei Mizuno,&nbsp;Satoshi Morita,&nbsp;Takashi Kobayashi,&nbsp;Takashi Mizowaki","doi":"10.1002/bco2.70074","DOIUrl":"10.1002/bco2.70074","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To develop a novel risk score (RS) model to predict the probability of progression to castration-resistant prostate cancer (PCa) (CRPC) after intensity-modulated radiation therapy (IMRT) for patients with high- and very high-risk PCa according to the National Comprehensive Cancer Network (NCCN) risk classification, since accurate prediction of the clinical outcome of definitive radiation therapy for patients with high- and very high-risk PCa remains challenging due to its heterogeneity.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>We conducted a retrospective review of 600 patients with high- and very high-risk PCa treated with IMRT at our institution. They were randomly divided into discovery (n = 300) and validation (n = 300) cohorts. A predictive RS model was created using a dataset from the discovery cohort based on the following parameters: T-stage, Gleason score, prostate-specific antigen and age at initiation of IMRT. The model was internally validated using a dataset from the validation cohort. RS was calculated using multivariable Cox regression analysis, and patients were categorized into low-risk, intermediate-risk or high-risk based on the value.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The median follow-up period of the 600 patients was 9.1 (IQR: 6.1–11.6) years. The 10-year CRPC-free rates for low-, intermediate- and high-risk categories were 100.0, 90.4 and 61.4% in the discovery cohort, respectively (p &lt; 0.001). Such differences were reproduced in the validation cohort. Specifically, those rates for low-, intermediate- and high-risk categories were 96.4, 90.7 and 74.8% in the validation cohort, respectively (p &lt; 0.001). Harrell's C-index for this model was 0.692, being higher than that of the NCCN risk classification (0.617).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This RS model provided useful information to enable tailoring of the treatment intensity for this heterogeneous population.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72420,"journal":{"name":"BJUI compass","volume":"6 9","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://bjui-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/bco2.70074","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145012306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hydrodissection using 10% dextrose before focal therapy of prostate cancer: Initial experience","authors":"Julien Anract,&nbsp;Marie Florin,&nbsp;Laura Larnaudie,&nbsp;Michael Peyromaure,&nbsp;Nicolas Barry Delongchamps","doi":"10.1002/bco2.70073","DOIUrl":"10.1002/bco2.70073","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To evaluate the feasibility and safety of hydrodissection of the prostato-rectal space using 10% dextrose for focal therapy of posterior prostate tumours.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Patients and methods</h3>\u0000 \u0000 <p>We included consecutive patients who underwent focal therapy for a posterior prostate tumour with a prior injection of 10% dextrose in the prostato-rectal space, between October 2024 and February 2025. The main outcomes were to evaluate the space created using this technique. As the technique used for hydrodissection was modelled on periprostatic nerve block, we analysed a cohort of patients who underwent transperineal prostate biopsies with periprostatic nerve block using 20 ml of lidocaine, to compare the prostato-rectal spaces created by 10% dextrose and by lidocaine.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 11 patients underwent a focal therapy with a prior 20 ml 10% dextrose hydrodissection of the prostato-rectal space. Fifteen patients who underwent prostatic biopsies using a periprostatic nerve block (20 ml of lidocaine), with similar characteristics, were included. The median prostato-rectal space created with dextrose and with lidocaine was 8.9 [8.0; 9.9] and 6.7 [6.4; 8.4] mm, respectively (p = 0,17). The prostato-rectal space decreased slower with dextrose: 0.03 mm/min vs 0.1 mm/min (p = 0,02). The prostato-rectal space was higher at the end of focal therapy procedures (7.9 vs 6.6 mm, p = 0,033), despite a longer procedure time in focal therapy (37 vs 8 min, p &lt; 0,001). At the end of focal therapy procedures, all patients had a prostato-rectal space &gt; 5 mm. No hydrodissection-related adverse event was observed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>These initial results suggest that hydrodissection of the prostate–rectal space using 20 ml 10% dextrose, injected following a standard periprostatic nerve block protocol, is feasible, reproducible and safe for a focal therapy procedure for localized posterior prostate tumours.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72420,"journal":{"name":"BJUI compass","volume":"6 9","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://bjui-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/bco2.70073","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144929615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From collection to correction: Can serial 24-hour urine collections demonstrate improved urinary stone parameters?","authors":"Daniel Jhang,&nbsp;Jason Groegler,&nbsp;Akin S. Amasyali,&nbsp;Hyukje Sung,&nbsp;Matthew Buell,&nbsp;Jersey Castillo,&nbsp;Elizabeth A. Baldwin,&nbsp;Mohamed Keheila,&nbsp;Zhamshid Okhunov,&nbsp;D. Duane Baldwin","doi":"10.1002/bco2.70070","DOIUrl":"10.1002/bco2.70070","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To determine whether serial 24-hour urine collections from the same patient over time result in improved stone risk parameters.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Patients and Methods</h3>\u0000 \u0000 <p>Using a 24-hour urinalysis database, 1832 tests from 688 patients collected over a 10-year period were retrospectively reviewed. Patients included in the analysis had a minimum follow-up of 2 years and at least three 24-hour urine collections. Changes in risk parameters were evaluated over time with each patient acting as their own control. Statistical analysis was performed using repeated measures ANOVA with a Greenhouse–Geisser correction and post-hoc analysis with Bonferroni correction. Significance level was set as p &lt; 0.05.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 225 patients had at least three 24-hour urine collections, of which 48% were female. From the first to the second 24-hour urine collections, volume and supersaturation of CaOx, CaP and UA all significantly improved (p &lt; 0.05). From the second to the third collection, only the supersaturation of CaP significantly improved (p &lt; 0.05). Approximately half of the patients continued to see improvement in stone risk parameters between the second and third urine collection.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Serial 24-hour urine collections performed at 6-month or greater intervals were significantly associated with improvements in stone risk parameters. This study suggests that serial collections can aid in the correction of urinary stone parameters and should be considered in active stone formers.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72420,"journal":{"name":"BJUI compass","volume":"6 8","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://bjui-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/bco2.70070","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144905544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of p-Tm:YAG, TFL and Ho:YAG's in vitro ablation rates on synthetic and human stones","authors":"Frédéric Panthier,&nbsp;Alba Sierra,&nbsp;Etienne Xavier Keller,&nbsp;Marie Chicaud,&nbsp;Eugenio Ventimiglia,&nbsp;Jia-Lun Kwok,&nbsp;Vincent De Coninck,&nbsp;Mariela Corrales,&nbsp;Michel Daudon,&nbsp;Cyril Gorny,&nbsp;Steeve Doizi,&nbsp;Laurent Berthe,&nbsp;Daron Smith,&nbsp;Olivier Traxer","doi":"10.1002/bco2.70067","DOIUrl":"10.1002/bco2.70067","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To compare in vitro the ablation rates of p-Tm:YAG, TFL and Ho:YAG against synthetic and human stones.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Material and Methods</h3>\u0000 \u0000 <p>p-Tm:YAG, TFL and Low-Power (LP) Ho:YAG were compared using 270 μm core-diameter laser fibres (CDF); experiments with 200 μm(p-Tm:YAG) and 150 μm-CDF (TFL) were also included. A continuous laser emission was applied through a spiral trajectory for 20 seconds with the laser fibre tip in contact with synthetic hard (HSP) and soft stone phantoms (SSP) submerged in saline. “Dusting” settings for p-Tm:YAG(0,6 J-20 Hz-Flex Long Pulse), TFL(0,5 J-30 Hz-Short Pulse) and Ho:YAG(0,5 J-30 Hz-Long Pulse) and “Fragmentation” settings for p-Tm:YAG(1 J-15 Hz-Captive), TFL(1 J-15 Hz-Short Pulse) and Ho:YAG(1 J-15 Hz-Long Pulse) were analysed. Then, experiments for human calcium oxalate monohydrate (COM), uric acid (UA) and cystine (CYS) stones were performed with single laser pulses at 0.6 J, 0.8 J and 1.0 J for p-Tm:YAG (Captive Fragmenting mode), TFL (Short Pulse) and Ho:YAG (Long Pulse). Synthetic and human stone samples were dried before three-dimensional scanning to measure ablation rates (ARs) and ablation volume per pulse (AVP).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>For synthetic stones with 270 μm-CDF, the p-Tm:YAG and TFL presented similar ARs, except in Fragmentation against HSP (95,1 ± 13,6vs67 ± 14 p = 0,02, respectively). Both p-Tm:YAG and TFL achieved higher ARs than Ho:YAG in all settings. p-Tm:YAG-200 μm-CDF and TFL-150 μm-CDF presented similar ARs, except in Fragmentation against HSP(78,4 ± 8vs42,5 ± 2,6 mm³/min,p = 0,0002). Both p-Tm:YAG-200 μm-CDF and TFL-150 μm-CDF presented at least 50% higher ARs than 270 μm-Ho:YAG. For human stones with COM, TFL exhibited higher AVP compared to p-Tm:YAG and Ho:YAG across all pulse energies (258,2 ± 213vs81,7 ± 31,9vs41,5 ± 25,4 μm³ p = 0,01, respectively). Against UA, Ho:YAG demonstrated higher AVP compared to TFL and p-Tm:YAG (355,2 ± 161vs99,8 ± 76,7vs292,9 ± 203,1 μm³ p = 0,0005, respectively). For CYS, Ho:YAG presented higher AVP but without significance (99,8 ± 76,7 vs 49,3 ± 36,3 vs 38,8 ± 12,2 μm³, p = 0,09).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>p-Tm:YAG and TFL achieved higher ARs than LP-Ho:YAG against synthetic stones in vitro. For human stones, TFL achieved the highest AVP against COM while LP-Ho:YAG delivered higher AVPs against UA and CYS, for which TFL performed worst.</p>\u0000 </section>\u0000 </div>","PeriodicalId":72420,"journal":{"name":"BJUI compass","volume":"6 8","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://bjui-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/bco2.70067","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144869122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}